The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia.

The effects of recombinant human growth hormone (rhGH) treatment for three years were compared in patients with achondroplasia (ACH) and hypochondroplasia (HCH), whose diagnosis had been confirmed by DNA analysis of the fibroblast growth factor receptor 3 gene. Height SDS (H-SDS) and height velocity SDS (HV-SDS) using the standard for ACH significantly improved during three-year treatment as compared with that before treatment in both ACH and HCH except HV-SDS in the third year. The improvement was much greater in HCH than in ACH. The mean increase H-SDS using the standard for ACH in three years in ACH (from -0.2 SD to 0.1 SD) is almost negligible but that in HCH (from 1.2 SD to 2.6 SD) can be estimated as effective clinically. It can be concluded short-term GH treatment in HCH is effective to increase growth rate and H-SDS, but it has little effect in ACH. Further studies would be required to confirm the other beneficial effects of GH treatment such as increase in bone mineral density in ACH and HCH and the effect on the final height.

[1]  Hiroyuki Tanaka,et al.  Growth Hormone Therapy in Achondroplasia , 2000, Hormone Research in Paediatrics.

[2]  U. Ramaswami,et al.  Growth hormone therapy in hypochondroplasia , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[3]  J. Gusella,et al.  The gene for achondroplasia maps to the telomeric region of chromosome 4p , 1994, Nature Genetics.

[4]  A. Munnich,et al.  Common Mutations in the Fibroblast Growth Factor Receptor 3 (FGFR 3) Gene Account for Achondroplasia, Hypochondroplasia and Thanatophoric Dwarfism , 1997 .

[5]  Jean Weissenbach,et al.  A gene for achondroplasia–hypochondroplasia maps to chromosome 4p , 1994, Nature Genetics.

[6]  D. Rimoin,et al.  Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. , 1996, The Journal of clinical endocrinology and metabolism.

[7]  P. Hindmarsh,et al.  Growth and Growth Hormone Therapy in Hypochondroplasia , 1990, Acta paediatrica Scandinavica.

[8]  I. Kaitila,et al.  A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia , 1995, Nature Genetics.

[9]  P. Hindmarsh,et al.  Genotype and phenotype in hypochondroplasia. , 1998, The Journal of pediatrics.

[10]  K Ashizawa,et al.  Setting up an automated system for evaluation of bone age. , 1999, Endocrine journal.

[11]  P. Prinos,et al.  A common FGFR3 gene mutation in hypochondroplasia. , 1995, Human molecular genetics.

[12]  J. Rotter,et al.  Standard growth curves for achondroplasia. , 1978, The Journal of pediatrics.

[13]  S. Kanzaki,et al.  Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. , 1998, European journal of endocrinology.

[14]  Toshiaki Tanaka,et al.  Four-year Experience of Growth Hormone Treatment in Children with Non-endocrine Short Stature , 1996 .

[15]  L. Key,et al.  Response to growth hormone in children with chondrodysplasia. , 1996, The Journal of pediatrics.

[16]  P. Hindmarsh,et al.  Treatment of Achondroplasia with Growth Hormone: Six Years of Experience , 1999, Pediatric Research.

[17]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[18]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[19]  D. Rimoin,et al.  The phenotypic variability of diastrophic dysplasia. , 1978, The Journal of pediatrics.

[20]  A. Lindahl,et al.  Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. , 1987, Endocrine reviews.

[21]  K. Tachibana,et al.  Longitudinal Standards for Height and Height Velocity for Japanese Children from Birth to Maturity , 1992 .

[22]  W. Blum,et al.  The differential regulation of the circulating levels of the insulin‐like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery , 1996, Clinical endocrinology.

[23]  G. Saggese,et al.  Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. , 1995, Hormone research.